Article Text

PDF
JournalScan
  1. Alistair Lindsay, Editor

Statistics from Altmetric.com

GENERAL CARDIOLOGY

Anticholinergics increase risk of cardiovascular death

Inhaled anticholinergics—such as ipratropium or tiotropium bromide—are commonly prescribed to patients with chronic obstructive pulmonary disease (COPD). A previous analysis of 19 short-term, placebo-controlled trials had suggested a possible increased risk of stroke with inhaled tiotropium, therefore Singh et al performed a meta-analysis of 17 trials enrolling 14 783 patients to ascertain the cardiovascular risks of inhaled anticholinergics.

Follow-up duration ranged from 6 weeks to 5 years. Cardiovascular death, myocardial infarction, or stroke occurred in 135 of 7472 patients (1.8%) receiving inhaled anticholinergics and 86 of 7311 patients (1.2%) receiving control treatment (relative risk 1.58; p<0.001). Specifically, anticholinergic therapy significantly increased the risk of myocardial infarction (relative risk 1.53, p = 0.03) and cardiovascular death (relative risk 1.80, p = 0.008) without a significant increase in the risk of stroke (relative risk 1.46, p = 0.20). All-cause mortality was reported in 149 of the patients taking anticholinergics (2.0%) and 115 of the control patients (1.6%, relative risk 1.26, p = 0.06), and a sensitivity analysis restricted to only the long-term trials confirmed the increased risk of cardiovascular death, myocardial infarction, or stroke (2.9% vs 1.8%; p<0.001).

Most of the excess risk was found to come when anticholinergics were taken for at least 6 months. Although the risk of cardiovascular death increased by some 80%, anticholinergics can significantly improve symptoms of breathlessness in patients with COPD. As a result, any risk associated with their use may still remain acceptable to some patients. Further information on this risk should be obtained from the upcoming UPLIFT (Understanding Potential Long-term Impacts on Function with Tiotropium) study.

▸ Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.